secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2024-10-11T23:59:59+00:00
Accession:  0000950170-24-114213
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon doses first patient in Phase 1 trial of WEE1/PKMYT1 inhibitor ACR-2316
------------------------------------------------------------------------------

- First patient dosed two quarters ahead of original timeline for ACR-2316 Phase 1 trial in solid tumors.
- ACR-2316 advanced from initial lead to Phase 1 in 15 months using AP3 platform.
- Initial clinical data from monotherapy dose optimization expected in 2H 2025.
- Trial assesses safety, tolerability, MTD, RP2D, PK, and anti-tumor activity per FDA Project Optimus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024114213/0000950170-24-114213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024114213/acrv-20241011.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-114213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer